Open AccessMoxalactam (LY127935) in treatment of meningitis due to gram-negative bacilli
Author(s) -
John F. Fisher,
M J Carter,
Joshua B. Parsons,
J. Peter Rissing
Publication year - 1981
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.19.2.218
Subject(s) - moxalactam , meningitis , aminoglycoside , medicine , cerebrospinal fluid , antibiotics , microbiology and biotechnology , serratia marcescens , cephalosporin , chemistry , biology , surgery , biochemistry , escherichia coli , gene
Moxalactam (LY127935; 6059S), a new broad-spectrum beta-lactam antibiotic, was used successfully with an aminoglycoside in a patient with Serratia marcescens meningitis complicating a neurosurgical procedure. With a bioassay method, peak and trough serum and cerebrospinal; fluid concentrations of moxalactam were determined during therapy. Mean peak and trough serum levels were 100.6 and 35.5 micrograms/ml, respectively. Corresponding mean peak and trough cerebrospinal fluid levels were 12.4 and 10.38 micrograms/ml. Cerebrospinal fluid levels of moxalactam exceeded the minimal bactericidal concentration for the infecting organism by more than 30-fold throughout therapy. No untoward effects of moxalactam were observed. Moxalactam may be a useful agent in the treatment of meningitis due to susceptible gram-negative bacilli.